32

BrainStorm

January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at [email protected].
 

Support the show

BrainStorm Feed

97
November 4, 2025 | 25:48

The Right to Choose - Diane Rehm on Autonomy, Aging, and End-of-Life Dignity

Diane Rehm, the legendary 89-year-old NPR talk show host, discusses her passionate advocacy for medical aid in dying with BrainStorm host, Meryl Comer. Rehm’s view

LISTEN NOW
96
October 21, 2025 | 21:55

The Menopause-Alzheimer's Connection: Why Timing Matters for Women's Brain Health with Dr. Rachel Buckley (part 2)

Dr. Rachel Buckley discusses the critical link between menopause and Alzheimer's risk in women with BrainStorm host Meryl Comer. Dr. Buckley explains that early menopause

LISTEN NOW
95
October 7, 2025 | 20:40

Women, Menopause, and Alzheimer's Risk: Breakthrough Research on Brain Health with Dr. Rachel Buckley (part 1)

Dr. Rachel Buckley of Mass General Hospital and Harvard Medical School discusses groundbreaking research revealing stark sex differences in Alzheimer's disease with BrainStorm host Meryl Comer.
LISTEN NOW